Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients

American Journal of Neurodegenerative Diseases

Volumn 2, Issue 2, 2013, Pages 129-139

  Fiala, Milan ^a   Mizwicki, Mathew T ^a   Weitzman, Rachel ^a   Magpantay, Larry ^a   Nishimoto, Norihiro ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

ActemraR; Amyotrophic lateral sclerosis; Caspase1; CCL20; CCL24; Interleukin1; Interleukin6; Macrophage; Superoxide dismutase1; Tocilizumab

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN 2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 23P19; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; TOCILIZUMAB;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE INCREASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MYELITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84980053734     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR and Appel SH. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 2004; 55: 221-235.
2. Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenco E, Eskin A, Liu PT, Magpantay L, Tse S, Mahanian M, Weitzman R, Tong J, Nguyen C, Cho T, Koo P, Sayre J, Martinez-Maza O, Rosenthal MJ and Wiedau-Pazos M. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation 2010; 7: 76-90.
3. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhyay M, La Cava A and Wiedau-Pazos M. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis 2012; 1: 60-74.
4. Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Liu G, Siani A, Chan D, Martinez-Maza O, Chattopadhyay M, La Cava A. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis 2012; 1: 305-15.
5. Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, Liao B and Appel SH. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011; 134: 1293-1314.
6. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009; 65 Suppl 1: S3-9.
7. Audet JN, Gowing G, Paradis R, Soucy G and Julien JP. Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase. PLoS One 2012; 7: e34932.
8. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD and Drachman DB. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006; 60: 22-31.
9. Serhan CN and Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 2011; 111: 5922-5943.
10. Levy BD, Clish CB, Schmidt B, Gronert K and Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2: 612-619.
11. Nishimoto N, Ito K and Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010; 20: 222-232.
12. Jones SA, Scheller J and Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375-3383.
13. Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G and Hartung HP. Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica: Implication for Cellular Immune Responses. Arch Neurol 2012; 1-4.
14. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-299.
15. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B and Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13-21.
16. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakehi T, Takagi N and Kishimoto T. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003; 30: 1426-1435.
17. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N and Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-3964.